Elevation Oncology Stock Performance
| ELEV Stock | USD 0.53 0.03 6.00% |
The firm shows a Beta (market volatility) of 1.41, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Elevation Oncology will likely underperform. At this point, Elevation Oncology has a negative expected return of -0.2%. Please make sure to confirm Elevation Oncology's jensen alpha, skewness, relative strength index, as well as the relationship between the value at risk and day median price , to decide if Elevation Oncology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Elevation Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
1 | Disposition of 12563 shares by Joseph Ferra of Elevation Oncology subject to Rule 16b-3 | 12/16/2024 |
2 | NEC X Invests in MarTech Startup, Clikr, Newest Graduate of Elev X Ignite Venture Studio Program | 12/18/2024 |
3 | Block upgraded, Bumble downgraded Wall Streets top analyst calls | 01/03/2025 |
4 | Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones | 01/13/2025 |
5 | Vanguard Group Inc. Reduces Stake in Elevation Oncology Inc. | 01/31/2025 |
6 | BlackRock, Inc. Increases Stake in Elevation Oncology Inc - GuruFocus.com | 02/05/2025 |
7 | Disposition of 25000 shares by Joseph Ferra of Elevation Oncology subject to Rule 16b-3 | 02/14/2025 |
8 | Disposition of 9211 shares by Joseph Ferra of Elevation Oncology at 0.6717 subject to Rule 16b-3 | 02/19/2025 |
9 | Can Elevation Oncologys March Conference Appearances Reveal New Cancer Treatment Progress - StockTitan | 02/25/2025 |
10 | Acquisition by Carruthers R Michael of 31238 shares of Elevation Oncology at 1.47 subject to Rule 16b-3 | 02/26/2025 |
11 | Elevation Oncology Inc Reports Q4 2024 Net Loss of 10. ... | 03/06/2025 |
12 | Elevation Oncology Reports 2024 Financial Results and Progress - TipRanks | 03/07/2025 |
13 | Elevation Oncologys Buy Rating Reiterated at HC Wainwright | 03/13/2025 |
| Begin Period Cash Flow | 49.3 M |
Elevation |
Elevation Oncology Relative Risk vs. Return Landscape
If you would invest 67.00 in Elevation Oncology on December 17, 2024 and sell it today you would lose (14.00) from holding Elevation Oncology or give up 20.9% of portfolio value over 90 days. Elevation Oncology is currently does not generate positive expected returns and assumes 6.3294% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Elevation, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Elevation Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Elevation Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Elevation Oncology, and traders can use it to determine the average amount a Elevation Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0317
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ELEV |
Estimated Market Risk
| 6.33 actual daily | 56 56% of assets are less volatile |
Expected Return
| -0.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Elevation Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Elevation Oncology by adding Elevation Oncology to a well-diversified portfolio.
Elevation Oncology Fundamentals Growth
Elevation Stock prices reflect investors' perceptions of the future prospects and financial health of Elevation Oncology, and Elevation Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Elevation Stock performance.
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | (30.55 M) | ||||
| Shares Outstanding | 59.22 M | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 0.52 X | ||||
| EBITDA | (44.7 M) | ||||
| Net Income | (44.48 M) | ||||
| Cash And Equivalents | 122.54 M | ||||
| Cash Per Share | 5.26 X | ||||
| Total Debt | 31.13 M | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 1.01 X | ||||
| Cash Flow From Operations | (36.36 M) | ||||
| Earnings Per Share | (0.78) X | ||||
| Market Capitalization | 31.55 M | ||||
| Total Asset | 95.63 M | ||||
| Retained Earnings | (240.46 M) | ||||
| Working Capital | 90.26 M | ||||
About Elevation Oncology Performance
Evaluating Elevation Oncology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Elevation Oncology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Elevation Oncology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.49) | (0.51) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.74) | (0.70) |
Things to note about Elevation Oncology performance evaluation
Checking the ongoing alerts about Elevation Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Elevation Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Elevation Oncology generated a negative expected return over the last 90 days | |
| Elevation Oncology has high historical volatility and very poor performance | |
| Elevation Oncology has some characteristics of a very speculative penny stock | |
| Elevation Oncology has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (44.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Elevation Oncology currently holds about 122.54 M in cash with (36.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Elevation Oncology has a frail financial position based on the latest SEC disclosures | |
| Roughly 68.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Elevation Oncologys Buy Rating Reiterated at HC Wainwright |
- Analyzing Elevation Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Elevation Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Elevation Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Elevation Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Elevation Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Elevation Oncology's stock. These opinions can provide insight into Elevation Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.